Is It The End For INR?

Treating patients with warfarin has always been a problem.  Even frequent regular INR testing fails to result in the majority of patients having clotting times within the recommended limits all the time. Now, all that could …

Read More

Think Differently

This was the title of a one day conference held to publicise the new anti-diabetic drug, dapagliflozin.  Quite a good title really seeing the novel approach of the drug to inhibit the reabsorption of glucose in …

Read More

Me Too!

The long term management of COPD has been affected by the latest “me-too” drug to be announced.  Until now the only long-acting anti-muscarinic drug available was tioptropium. Until now, Boehringer-Ingelheim have had this important field to …

Read More

Full of (Kidney) Beans!

People interested in diabetes are always talking about eyes, feet or kidneys. At the present time, the interest is in kidneys. That’s not to say that eyes and feet have taken a back seat. It’s just …

Read More

That Helsinki Feeling

Linda Goldie, one of our Clinical Directors, is in Helsinki at the moment. Here’s what she’s up to: “I am here representing the general practice in which I work as a Diabetes Specialist Practice Nurse. This …

Read More